Cantabio Pharmaceuticals, Inc. (CTBO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cantabio Pharmaceuticals, Inc. (CTBO) with AI Score 50/100 (Hold). Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company focused on developing therapies for neurodegenerative diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cantabio Pharmaceuticals, Inc. (CTBO) Healthcare & Pipeline Overview
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology firm, pioneers novel therapies for Parkinson's and Alzheimer's diseases. With a focus on pharmacological chaperones, Cantabio targets DJ-1 and Tau proteins, positioning itself in the competitive neurodegenerative disease treatment landscape. The company's collaboration with the Luxembourg Institute of Health expands its research scope.
Investment Thesis
Cantabio Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity typical of preclinical stage biotechnology companies. The company's focus on novel therapies for Parkinson's and Alzheimer's diseases, using a pharmacological chaperone approach, targets significant unmet medical needs. The value drivers include successful preclinical development of its lead programs (CB101, CB201, CB301, and CB401) and progression into Phase 1 clinical trials. Key catalysts include IND (Investigational New Drug) application submissions to the FDA and subsequent clinical trial initiations, expected within the next 12-24 months. A collaboration with the Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 protein to treat immune-associated diseases could provide additional value. The company's market capitalization of $0.00B reflects its early stage, but successful clinical data could drive significant appreciation. However, the company's negative free cash flow of $-0.00B highlights the need for additional funding, posing a potential risk of dilution for existing shareholders.
Based on FMP financials and quantitative analysis
Key Highlights
- Cantabio Pharmaceuticals is a preclinical stage biotechnology company focused on neurodegenerative diseases.
- The company's lead programs target DJ-1 and Tau proteins implicated in Parkinson's and Alzheimer's diseases.
- Cantabio utilizes a pharmacological chaperone approach to develop novel therapies.
- The company has a collaboration agreement with the Luxembourg Institute of Health to research immune-associated diseases.
- Cantabio Pharmaceuticals is based in Palo Alto, California, a hub for biotechnology innovation.
Competitors & Peers
Strengths
- Novel pharmacological chaperone technology.
- Focus on validated drug targets (DJ-1, Tau).
- Collaboration with Luxembourg Institute of Health.
- Early-stage pipeline with significant potential.
Weaknesses
- Preclinical stage company with no approved products.
- High reliance on external funding.
- Limited clinical data.
- Small market capitalization.
Catalysts
- Upcoming: IND application submission for CB101 (Parkinson's disease) within the next 12 months.
- Upcoming: Initiation of Phase 1 clinical trial for CB101 (Parkinson's disease) within the next 18 months, pending IND approval.
- Upcoming: Preclinical data release for CB301 (Alzheimer's disease) within the next 6-9 months.
- Ongoing: Collaboration with the Luxembourg Institute of Health to research DJ-1 protein in immune-associated diseases.
- Ongoing: Continued development and optimization of pharmacological chaperone technology.
Risks
- Potential: Clinical trial failures for lead programs (CB101, CB301).
- Potential: Regulatory hurdles and delays in obtaining FDA approval.
- Potential: Competition from other biotechnology and pharmaceutical companies developing therapies for Parkinson's and Alzheimer's diseases.
- Ongoing: Inability to secure additional funding to support research and development activities.
- Ongoing: Dependence on key personnel and collaborators.
Growth Opportunities
- Advancement of CB101 into Clinical Trials: Cantabio's lead program, CB101, a DJ-1 targeting small molecule pharmacological chaperone for Parkinson's disease, represents a significant growth opportunity. The Parkinson's disease market is projected to reach $5.6 billion by 2027. Successful completion of preclinical studies and subsequent initiation of Phase 1 clinical trials within the next 12-18 months could significantly increase the company's valuation and attract partnerships. The company's novel approach to targeting DJ-1 offers a potential competitive advantage.
- Development of CB301 for Alzheimer's Disease: CB301, a Tau protein targeting small molecule pharmacological chaperone for Alzheimer's disease, addresses a massive market with substantial unmet needs. The global Alzheimer's disease market is expected to reach $12.6 billion by 2028. Positive preclinical data and progression into clinical trials within the next 2 years could position Cantabio as a key player in this space. The company's focus on Tau protein, a key pathological hallmark of Alzheimer's, differentiates it from other approaches.
- Expansion of DJ-1 Platform into Immune-Associated Diseases: Cantabio's collaboration with the Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 protein to treat immune-associated diseases opens up new growth avenues. The market for immune-associated disease therapies is substantial, with autoimmune diseases affecting millions worldwide. Preclinical studies demonstrating efficacy in relevant models within the next 18-24 months could lead to further collaborations and licensing opportunities.
- Strategic Partnerships and Licensing Agreements: Cantabio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Licensing agreements for specific programs or technologies could provide non-dilutive funding and validation of the company's approach. Securing a significant partnership within the next year could significantly enhance the company's financial position and development capabilities.
- Expansion of Pipeline with Novel Targets: Cantabio can leverage its expertise in pharmacological chaperones to expand its pipeline with novel targets for other neurodegenerative diseases. Identifying and validating new targets within the next 24 months could create additional value and diversify the company's risk profile. This could involve exploring targets beyond DJ-1 and Tau, addressing other key pathological mechanisms in neurodegenerative disorders.
Opportunities
- Advancement of lead programs into clinical trials.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline with novel targets.
- Licensing agreements for specific programs or technologies.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology and pharmaceutical companies.
- Inability to secure additional funding.
Competitive Advantages
- Proprietary small molecule pharmacological chaperone technology.
- Focus on validated drug targets (DJ-1, Tau) in neurodegenerative diseases.
- Collaboration with the Luxembourg Institute of Health provides access to unique research capabilities.
- Early-stage pipeline with potential for significant upside.
About CTBO
Cantabio Pharmaceuticals, Inc., founded in 2009 and based in Palo Alto, California, is a preclinical stage biotechnology company dedicated to the research, development, and potential commercialization of innovative therapies for neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease (AD). The company's core strategy revolves around developing small molecule pharmacological chaperones that target specific proteins implicated in these diseases. Cantabio's lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone designed for the treatment of PD. CB201, another program, features a CNS penetrant engineered DJ-1 protein, also aimed at treating PD. For Alzheimer's disease, Cantabio is developing CB301, a Tau protein targeting small molecule pharmacological chaperone, and CB401, an Aß targeting small molecule pharmacological chaperone. These programs are currently in the preclinical stage, indicating that they are undergoing laboratory testing and animal studies to assess their safety and efficacy before human clinical trials. In addition to its internal research and development efforts, Cantabio Pharmaceuticals has established a collaboration agreement with the Luxembourg Institute of Health. This collaboration focuses on researching the therapeutic targeting of the DJ-1 protein to treat immune-associated diseases, expanding the potential applications of Cantabio's technology beyond neurodegenerative disorders. Cantabio is positioning itself to address significant unmet medical needs in the treatment of debilitating conditions.
What They Do
- Researches and develops novel therapies for Parkinson's disease.
- Develops treatments for Alzheimer's disease.
- Focuses on small molecule pharmacological chaperones.
- Targets DJ-1 protein for Parkinson's disease.
- Targets Tau protein for Alzheimer's disease.
- Collaborates with research institutions to expand therapeutic applications.
Business Model
- Develops proprietary drug candidates for neurodegenerative diseases.
- Out-licenses or partners with larger pharmaceutical companies for clinical development and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
Industry Context
The biotechnology industry is characterized by high R&D spending, long development timelines, and significant regulatory hurdles. The market for neurodegenerative disease therapies is substantial and growing, driven by an aging global population. Parkinson's disease and Alzheimer's disease represent major unmet medical needs, with limited effective treatments currently available. Cantabio Pharmaceuticals competes with other biotechnology and pharmaceutical companies developing therapies for these diseases. The company's success depends on its ability to successfully navigate the regulatory approval process and demonstrate clinical efficacy.
Key Customers
- Larger pharmaceutical companies seeking to in-license novel drug candidates.
- Patients suffering from Parkinson's disease.
- Patients suffering from Alzheimer's disease.
Financials
Chart & Info
Cantabio Pharmaceuticals, Inc. (CTBO) stock price: Price data unavailable
Latest News
No recent news available for CTBO.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTBO.
Price Targets
Wall Street price target analysis for CTBO.
MoonshotScore
What does this score mean?
The MoonshotScore rates CTBO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gergely Toth
CEO
Gergely Toth serves as the CEO of Cantabio Pharmaceuticals, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in several companies, focusing on drug development and commercialization. His expertise spans across various therapeutic areas, including neurodegenerative diseases. He has a strong track record in strategic planning, business development, and fundraising.
Track Record: Under Gergely Toth's leadership, Cantabio Pharmaceuticals has advanced its preclinical programs targeting Parkinson's and Alzheimer's diseases. He has overseen the company's collaboration with the Luxembourg Institute of Health and has been instrumental in securing funding for research and development activities. His strategic decisions have focused on leveraging the company's proprietary technology and expanding its pipeline.
CTBO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cantabio Pharmaceuticals may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies on this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in CTBO.
- Low trading volume and wide bid-ask spreads can make it difficult to exit a position.
- The OTC Other tier designation indicates a higher risk of fraud or mismanagement.
- The company may not meet the listing requirements of major exchanges, limiting future growth opportunities.
- The lack of regulatory oversight increases the potential for information asymmetry.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's cash runway and funding needs.
- Consult with a financial advisor to assess the risks and potential rewards of investing in CTBO.
- Confirm the company's legal standing and compliance with regulations.
- The company is incorporated and has a physical headquarters in Palo Alto, California.
- The company has a collaboration agreement with the Luxembourg Institute of Health.
- The company is focused on developing therapies for significant unmet medical needs.
- The company has a CEO with experience in the biotechnology industry.
- The company has a patent portfolio related to its core technology.
Common Questions About CTBO
What does Cantabio Pharmaceuticals, Inc. do?
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, specifically Parkinson's and Alzheimer's diseases. The company's approach centers around small molecule pharmacological chaperones that target specific proteins implicated in these diseases, such as DJ-1 and Tau. These chaperones aim to stabilize and restore the function of these proteins, potentially slowing or reversing disease progression. Cantabio's pipeline includes programs targeting both Parkinson's and Alzheimer's, with the goal of partnering with larger pharmaceutical companies for clinical development and commercialization.
What do analysts say about CTBO stock?
As a preclinical stage company trading on the OTC market, Cantabio Pharmaceuticals, Inc. is not widely covered by analysts. Investment in CTBO is highly speculative and dependent on the successful development and clinical validation of its lead programs. Key metrics to monitor include preclinical data, IND application submissions, and initiation of clinical trials. The company's valuation is largely based on the potential of its technology and pipeline, rather than current revenue or earnings. Investors should conduct thorough due diligence and consider the significant risks associated with investing in early-stage biotechnology companies.
What are the main risks for CTBO?
The main risks for Cantabio Pharmaceuticals, Inc. include the inherent uncertainties of drug development, particularly the high failure rate in clinical trials. The company's reliance on external funding to support its research and development activities poses a significant risk, as the inability to secure additional capital could delay or halt its programs. Competition from other biotechnology and pharmaceutical companies developing therapies for Parkinson's and Alzheimer's diseases is also a key risk. Regulatory hurdles and delays in obtaining FDA approval could further impact the company's prospects. Additionally, the company's OTC listing and limited financial disclosure increase investment risk.
What are the key factors to evaluate for CTBO?
Cantabio Pharmaceuticals, Inc. (CTBO) currently holds an AI score of 50/100, indicating moderate score. Key strength: Novel pharmacological chaperone technology.. Primary risk to monitor: Potential: Clinical trial failures for lead programs (CB101, CB301).. This is not financial advice.
How frequently does CTBO data refresh on this page?
CTBO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CTBO's recent stock price performance?
Recent price movement in Cantabio Pharmaceuticals, Inc. (CTBO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel pharmacological chaperone technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CTBO overvalued or undervalued right now?
Determining whether Cantabio Pharmaceuticals, Inc. (CTBO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CTBO?
Before investing in Cantabio Pharmaceuticals, Inc. (CTBO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis pending for CTBO, which may provide additional insights.